Insider Trading Alert - SYK, ULTI, PLCM, THOR And MU Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 4, 2013, 136 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $597.52 to $378,220,575.33.

Highlighted Stocks Traded by Insiders:

Stryker Corporation (SYK) - FREE Research Report

Stryker Ronda E who is Director at Stryker Corporation sold 14,000 shares at $73.99 on Nov. 4, 2013. Following this transaction, the Director owned 11.5 million shares meaning that the stake was reduced by 0.12% with the 14,000 share transaction.

The shares most recently traded at $74.09, up $0.10, or 0.13% since the insider transaction. Historical insider transactions for Stryker Corporation go as follows:

  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Stryker Corporation has been 1.3 million shares per day over the past 30 days. Stryker Corporation has a market cap of $28.0 billion and is part of the health care sector and health services industry. Shares are up 35.04% year to date as of the close of trading on Monday.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. The stock currently has a dividend yield of 1.43%. The company has a P/E ratio of 31.8. Currently there are 13 analysts that rate Stryker Corporation a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYK - FREE

TheStreet Quant Ratings rates Stryker Corporation as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Stryker Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal